In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exiting Generics

Executive Summary

Just a couple of years ago, generics were all the rage in pharmaceutical development programs. Big pharma companies scrambled for ways to create generics franchises that would enable them to offer a broad array of products to managed care customers. But now, with HMR's sale of its Rugby-Darby Group to Watson Pharmaceuticals, we seem to be in the midst of a major bail out. It's now clear that the smartest generics strategy is a no-generics strategy.
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV000751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel